Basilea Pharmaceutica AG
SIX:BSLN
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
39.45
58.6
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CHF.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one
BSLN
stock under the Base Case scenario is
50.55
CHF.
Compared to the current market price of 54.7 CHF,
Basilea Pharmaceutica AG
is
Overvalued by 8%.
Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.
Let our AI break down the key assumptions behind the intrinsic value calculation for Basilea Pharmaceutica AG.
Fundamental Analysis
BSLN Profitability Score
Profitability Due Diligence
Score
BSLN Solvency Score
Solvency Due Diligence
Score
Select up to 3 indicators:
Select up to 3 indicators:
Balance Sheet Decomposition
Basilea Pharmaceutica AG
Basilea Pharmaceutica AG
Free Cash Flow Analysis
Basilea Pharmaceutica AG
| CHF | |
| Free Cash Flow | CHF |
Earnings Waterfall
Basilea Pharmaceutica AG
Wall St
Price Targets
BSLN Price Targets Summary
Basilea Pharmaceutica AG
According to Wall Street analysts, the average 1-year price target for
BSLN
is 91.29 CHF
with a low forecast of 64.64 CHF and a high forecast of 126 CHF.
Dividends
Current shareholder yield for
BSLN is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
BSLN
stock under the Base Case scenario is
50.55
CHF.
Compared to the current market price of 54.7 CHF,
Basilea Pharmaceutica AG
is
Overvalued by 8%.